세계의 중증근무력증 치료 시장 : 예측 및 동향

Highlights:

The global market for myasthenia gravis treatment is estimated to increase from $1.3 billion in 2023 to reach $2.2 billion by 2028, at a compound annual growth rate (CAGR) of 10.5% from 2023 through 2028.

The global market for generalized myasthenia gravis treatment is estimated to increase from $1.1 billion in 2023 to reach $1.9 billion by 2028, at a compound annual growth rate (CAGR) of 10.6% from 2023 through 2028.

The global market for ocular myasthenia gravis treatment is estimated to increase from $102.4 million in 2023 to reach $159.6 million by 2028, at a compound annual growth rate (CAGR) of 9.3% from 2023 through 2028.

Report Scope:

This report aims to study the myasthenia gravis treatment global market size comprehensively. Current and historical market revenues can be estimated based on the product type, treatment by drug and region.

Report Includes:

• 54 data tables and 47 additional tables
• An overview and analysis of the global market for myasthenia gravis (MG) treatments
• Analyses of market trends, with historical market revenue data (sales figures) for 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
• Estimates of the market size, revenue forecasts and potential growth share analysis for MG treatments based on product, type, treatment modality, and region
• In-depth information (facts and figures) pertaining to the major factors influencing the market (drivers, restraints, opportunities and challenges)
• Analysis of the market growth opportunities through Porter's Five Forces and PESTLE analyses, taking into consideration the prevailing micro- and macro environmental factors
• An examination of the importance of ESG in the myasthenia gravis market, taking into account consumer attitudes, risks and opportunities, and the ESG practices of pharmaceutical and biotech companies
• Discussion of the factors driving the market, industry trends and new developments
• Analysis of relevant patents
• Identification of the leaders in the field of MG
• Profiles of the leading market players, including Profiles of the leading market players, including AbbVie, Bausch Health, Gilead Sciences, Merck & Co. Inc., Servier, and Teva

Table of Contents

Chapter 1 Introduction

• Study Goals and Objectives
• Reasons for Doing This Study
• Scope of Report
• Methodology
• Information Sources
• Primary Research
• Secondary Research
• Geographic Breakdown
• Segmentation Breakdown

Chapter 2 Summary and Highlights

• Market Outlook
• Report Highlights

Chapter 3 Market Overview

• Myasthenia Gravis
• Ocular Myasthenia Gravis
• Generalized Myasthenia Gravis
• Transient Neonatal Myasthenia Gravis
• Global Regulatory Structure for Myasthenia Gravis
• Drug Approvals and Regulation
• Clinical Trials
• Patient Access and Health Insurance
• Pharmaceutical Pricing and Reimbursement
• Clinical Practice Guidelines
• Rare Disease Designation
• Patient Advocacy and Support
• Pricing and Reimbursement for the Treatment of Myasthenia Gravis
• North America
• Europe
• Asia-Pacific
• Therapies/Drugs Used to Treat Myasthenia Gravis
• Medications
• Surgery
• Intravenous (IV) Therapy
• Medications

Chapter 4 Market Dynamics

• Market Drivers
• Growing Elderly Population
• Increasing Incidence and Prevalence
• Advancements in Myasthenia Gravis Diagnostics
• Research and Development
• Regulatory Environment
• Personalized Medicine
• Market Opportunities
• Unmet Medical Needs
• Advancements in Research and Development
• Biologics and Immunotherapies
• Global Expansion
• Increased Awareness
• Tailored Treatment Approaches
• Healthcare Reimbursement
• Patient-Centric Care
• Competitive Landscape
• Chronic Nature of Myasthenia Gravis
• Research Collaboration
• Market Restraints
• Limited Patient Population
• Diagnostic Challenges
• Lack of Disease-Modifying Therapies
• Reimbursement Issues
• Risks of Emerging Therapies
• Other Restraints

Chapter 5 Market Breakdown by Region

• Market Overview
• North America
• Europe
• Asia-Pacific

Chapter 6 Market Breakdown by Type

• Market Overview
• Generalized Myasthenia Gravis
• Transient Neonatal Myasthenia Gravis
• Ocular Myasthenia Gravis

Chapter 7 Market Breakdown by Treatment Modality

• Introduction
• Medications
• Surgery
• Intravenous Therapy

Chapter 8 Market Breakdown by Type of Product

• Monoclonal Antibodies
• Brands
• Cholinesterase Inhibitors
• Brand
• Intravenous Immunoglobulins
• Brands
• Immunosuppressants
• Brand
• Corticosteroids
• Brand

Chapter 9 ESG Development

• Introduction
• Environment
• Social
• Governance
• Case Study
• AstraZeneca
• Concluding Remarks from BCC Research

Chapter 10 Emerging Technologies and Developments

• Introduction

Chapter 11 Competitive Intelligence

• Overview
• Industry Scenario
• Company Shares

Chapter 12 Patent Analysis

• Patent Analysis by Manufacturer

Chapter 13 Pipeline Analysis

• Clinical Trials

Chapter 14 M&A and Venture Funding Outlook

• Introduction

Chapter 15 Company Profiles

• ABBVIE
• AMYASTHENIA GRAVISEN INC.
• ASTELLAS PHARMA INC.
• ASTRAZENECA
• BAUSCH HEALTH COMPANIES INC.
• BAYER AG
• BIOGEN
• BRISTOL-MYERS SQUIBB
• CSL
• DAIICHI SANKYO CO. LTD.
• F. HOFFMANN-LA ROCHE AG
• GILEAD SCIENCES INC.
• GLAXOSMITHKLINE PLC.
• MERCK & CO. INC.
• NOVARTIS
• PFIZER INC.
• SANOFI
• SERVIER LABORATORIES
• TEVA PHARMACEUTICAL INDUSTRIES LTD.

Chapter 16 Appendix: Acronyms